News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,885 Results
Type
Article (52744)
Company Profile (197)
Press Release (648944)
Multimedia
Podcasts (105)
Webinars (13)
Section
Business (200033)
Career Advice (3369)
Deals (35556)
Drug Delivery (123)
Drug Development (79211)
Employer Resources (188)
FDA (16113)
Job Trends (15381)
News (340605)
Policy (34136)
Tag
Academia (2880)
Accelerated approval (6)
Adcomms (28)
Allergies (92)
Alliances (48544)
ALS (104)
Alzheimer's disease (1454)
Antibody-drug conjugate (ADC) (153)
Approvals (16067)
Artificial intelligence (294)
Autoimmune disease (28)
Automation (15)
Bankruptcy (352)
Best Places to Work (12200)
BIOSECURE Act (22)
Biosimilars (117)
Biotechnology (127)
Bladder cancer (84)
Brain cancer (31)
Breast cancer (307)
Cancer (2441)
Cardiovascular disease (208)
Career advice (2837)
Career pathing (34)
CAR-T (169)
Cell therapy (474)
Cervical cancer (21)
Clinical research (64313)
Collaboration (902)
Company closure (2)
Compensation (516)
Complete response letters (29)
COVID-19 (2825)
CRISPR (49)
C-suite (275)
Cystic fibrosis (108)
Data (2383)
Decentralized trials (2)
Denatured (33)
Depression (55)
Diabetes (295)
Diagnostics (6706)
Digital health (20)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (131)
Drug pricing (132)
Drug shortages (32)
Duchenne muscular dystrophy (103)
Earnings (81434)
Editorial (47)
Employer branding (24)
Employer resources (160)
Events (109189)
Executive appointments (789)
FDA (17521)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (824)
Gene editing (123)
Generative AI (25)
Gene therapy (357)
GLP-1 (845)
Government (4916)
Grass and pollen (6)
Guidances (162)
Healthcare (20174)
Huntington's disease (25)
IgA nephropathy (32)
Immunology and inflammation (151)
Indications (30)
Infectious disease (2986)
Inflammatory bowel disease (154)
Inflation Reduction Act (12)
Influenza (56)
Intellectual property (101)
Interviews (648)
IPO (17045)
IRA (50)
Job creations (3601)
Job search strategy (2317)
Kidney cancer (11)
Labor market (45)
Layoffs (534)
Leadership (24)
Legal (8518)
Liver cancer (79)
Lung cancer (343)
Lymphoma (161)
Machine learning (9)
Management (63)
Manufacturing (361)
MASH (84)
Medical device (13879)
Medtech (13884)
Mergers & acquisitions (19125)
Metabolic disorders (797)
Multiple sclerosis (87)
NASH (23)
Neurodegenerative disease (117)
Neuropsychiatric disorders (35)
Neuroscience (2069)
NextGen: Class of 2025 (7124)
Non-profit (4903)
Now hiring (40)
Obesity (427)
Opinion (272)
Ovarian cancer (83)
Pain (98)
Pancreatic cancer (88)
Parkinson's disease (163)
Partnered (22)
Patents (253)
Patient recruitment (115)
Peanut (49)
People (58610)
Pharmaceutical (54)
Pharmacy benefit managers (23)
Phase I (19857)
Phase II (28394)
Phase III (21580)
Pipeline (1430)
Policy (181)
Postmarket research (2402)
Preclinical (8347)
Press Release (69)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (263)
Rare diseases (429)
Real estate (6025)
Recruiting (73)
Regulatory (23004)
Reports (46)
Research institute (2537)
Resumes & cover letters (555)
Rett syndrome (6)
RNA editing (4)
RSV (50)
Schizophrenia (83)
Series A (144)
Series B (98)
Service/supplier (19)
Sickle cell disease (58)
Special edition (20)
Spinal muscular atrophy (158)
Sponsored (33)
Startups (3951)
State (2)
Stomach cancer (16)
Supply chain (74)
Tariffs (57)
The Weekly (70)
Vaccines (809)
Venture capitalists (45)
Weight loss (301)
Women's health (35)
Worklife (20)
Date
Today (129)
Last 7 days (1002)
Last 30 days (3332)
Last 365 days (33382)
2025 (12360)
2024 (36188)
2023 (41184)
2022 (52535)
2021 (57175)
2020 (56109)
2019 (49596)
2018 (37712)
2017 (34195)
2016 (33478)
2015 (38841)
2014 (29865)
2013 (25467)
2012 (27176)
2011 (27885)
2010 (25371)
Location
Africa (950)
Alabama (59)
Alaska (7)
Arizona (209)
Arkansas (14)
Asia (41106)
Australia (6884)
California (6370)
Canada (2063)
China (559)
Colorado (282)
Connecticut (298)
Delaware (159)
Europe (94151)
Florida (963)
Georgia (227)
Hawaii (1)
Idaho (56)
Illinois (561)
India (28)
Indiana (330)
Iowa (10)
Japan (178)
Kansas (103)
Kentucky (24)
Louisiana (13)
Maine (67)
Maryland (942)
Massachusetts (4848)
Michigan (242)
Minnesota (388)
Mississippi (2)
Missouri (87)
Montana (29)
Nebraska (24)
Nevada (68)
New Hampshire (69)
New Jersey (1838)
New Mexico (26)
New York (1841)
North Carolina (1074)
North Dakota (8)
Northern California (2820)
Ohio (216)
Oklahoma (14)
Oregon (36)
Pennsylvania (1389)
Puerto Rico (14)
Rhode Island (31)
South America (1309)
South Carolina (27)
South Dakota (1)
Southern California (2400)
Tennessee (109)
Texas (944)
United States (24348)
Utah (185)
Virginia (157)
Washington D.C. (68)
Washington State (605)
West Virginia (3)
Wisconsin (61)
701,885 Results for "valneva se".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Vaccines
FDA, EU Flag Safety Issues With Valneva’s Chikungunya Vaccine
The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ongoing.
May 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
April 2, 2025
·
10 min read
Press Releases
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
May 12, 2025
·
6 min read
Press Releases
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
May 8, 2025
·
6 min read
Press Releases
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
April 28, 2025
·
6 min read
Press Releases
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 7, 2025
·
24 min read
Press Releases
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
April 15, 2025
·
10 min read
Press Releases
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
April 18, 2025
·
6 min read
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
Valneva SE announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.
May 31, 2024
·
9 min read
Press Releases
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
March 25, 2025
·
2 min read
1 of 70,189
Next
